Medical Oncology

Uzm. Dr. Uğur Özkerim

Doctor and researcher Kartal Dr. Lütfi Kırdar Şehir Hastanesi İstanbul
Breast Neoplasms
Open institution page
Suggest a correction

Is this your profile? Claim it and verify your details.

Claim profile

Person ↔ Disease

Which diseases does this doctor work on?

From source

Trust

Where does this information come from?

The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.

  • SpecialtyMedical Oncologysaglik.gov.trFrom source
  • InstitutionKartal Dr. Lütfi Kırdar Şehir Hastanesisaglik.gov.trFrom source
  • Area of workBreast NeoplasmsExtracted from 7 publications · Model version —From source
  • Publications30 publicationsOpenAlex, ORCIDFrom source
  • ORCID0000-0001-8527-1392ORCIDFrom source
  • Last synchronised5 November 2026 08:56https://lutfikirdareah.saglik.gov.tr/TR-1480911/doktorlarimiz.html#ugur-ozkerimsaglik.gov.tr

Scientific work

Publications on Breast Neoplasms

30 publications

  1. Association Between Time to PSA Nadir, Radiologic Progression, and PSA Progression in mHSPC Patients Treated with Abiraterone or Enzalutamide

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15010386 PMID 41517635 1 citation (Europe PMC) Open-access full textSource: OpenAlex

  2. Association between GRIm score and response to nivolumab monotherapy in patients with advanced malignant melanoma

    Journal of Cancer Research and Clinical Oncology, 2026

    DOI 10.1007/s00432-025-06411-7 PMID 41504775 3 citations (Europe PMC) Open-access full textSource: OpenAlex

  3. Impact of Peri-Immunotherapy Antibiotic Exposure on Survival Outcomes in Metastatic Renal Cell Carcinoma: A Real-World IMDC Risk–Stratified Analysis

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15051853 PMID 41827267 1 citation (Europe PMC) Open-access full textSource: OpenAlex

  4. FOLFOX Plus Bevacizumab Rechallenge Versus Regorafenib as Third-Line Treatment in Metastatic Colorectal Cancer: The Role of the Oxaliplatin-Free Interval

    Cancers, 2026

    DOI 10.3390/cancers18182987 PMID 42794953 Open-access full textSource: OpenAlex

  5. Pan‑immune‑inflammation value as a prognostic and predictive biomarker in metastatic non‑small cell lung cancer treated with nivolumab: A real‑world study

    Oncology Letters, 2026

    DOI 10.3892/ol.2026.15750 PMID 42491228 Open-access full textSource: ORCID

  6. 486P Machine learning–based prediction of nivolumab response using systemic inflammatory biomarkers in advanced NSCLC: A real-world study

    ESMO Open, 2026

    DOI 10.1016/j.esmoop.2026.106800 Open-access full textSource: OpenAlex

  7. 105P HER2 amplification drives resistance to anti-EGFR therapy in RAS/BRAF wild-type metastatic colorectal cancer: A real-world study

    Annals of Oncology, 2026

    DOI 10.1016/j.annonc.2026.05.106 Open-access full textSource: OpenAlex

  8. Prognostic Impact of Immune-Related Adverse Events in Patients with Non–Small Cell Lung Cancer Treated with Second-Line Nivolumab: A Single-Center Real-World Experience

    Eurasian Journal of Medical Investigation, 2026

    DOI 10.14744/ejmi.263046 Source: OpenAlex

  9. Pneumococcal Vaccination in Oncology Practice in Türkiye: Results of Patient and Physician Survey Studies

    Cerrahpaşa Medical Journal, 2026

    DOI 10.5152/cjm.2026.26011 Open-access full textSource: ORCID

  10. Significance of CEA Dynamics and Systemic Inflammatory Markers in HER2-Positive Metastatic Colorectal Cancer Patients Undergoing First-Line Chemotherapy: A Real-World Cohort Study

    Medicina, 2026

    DOI 10.3390/medicina62010099 PMID 41597386 1 citation (Europe PMC) Open-access full textSource: OpenAlex

View all 30 publications